We were grateful for the opportunity to attend and present at the AACR Annual Meeting last week, where three of our scientists highlighted some of the exciting work happening in our Vancouver lab.
October 24, 2022
We’re thrilled to announce that Imagia Canexia Health is a finalist for the Reuters Events Pharma Awards, in the Driving Health Equity category.
June 3, 2022
This article from BioWorld Medtech includes an interview with our CMO David Huntsman, where he discusses Imagia Canexia Health's Candetect project, which is developing precision oncology software that will help monitor resistance to cancer therapy and treatment relapse in individual cancer survivors.
February 4, 2021
This article from The Globe and Mail covers Project ACTT, a federally funded project, led by Canexia Health, which offers the potential for a more efficient alternative for cancer testing that can save hospital resources and lower the risk of infection.
August 27, 2020
DeciBio interviewed Canexia Health's Brady Davis to discuss how Canexia Health and Project ACTT (Access to Testing and Treatment) are leveraging Canexia’s tech transfer platform and liquid biopsy test, Follow IT, to bridge the gap between the Canadian cancer community and molecular testing during the COVID-19 pandemic.
August 7, 2020
British Columbia-based Digital Technology Supercluster has announced a cumulative investment of approximately $30 million into 17 projects, including Project ACTT led by Canexia Health, through its COVID-19 program, launched in April to contribute to Canada’s Plan to Mobilize Industry to fight the pandemic.
July 22, 2020
Canadian firm Canexia Health is hoping that its leadership of a countrywide effort to widen patient access to liquid biopsy testing during the COVID-19 pandemic.
July 16, 2020
A consortium led by Vancouver’s Canexia Health (formerly Contextual Genomics) will soon offer critical testing and treatment options for Canadian cancer patients during the COVID-19 pandemic.
July 16, 2020
In response to restricted access to critical diagnostics for cancer patients resulting from the COVID-19 pandemic, a Canadian consortium led by Canexia Health (formerly named Contextual Genomics) has launched Project ACTT (Access to Cancer Testing & Treatment).
Every Imagia Canexia Health report comes with therapeutic recommendations based on specific gene mutations and patient profiles, with clinical trials reviewed and selected by certified clinical molecular geneticists.